Loading...

PODCAST

Diabetes Discourse

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease. Because when it

science & medicine medicine

All Episodes

00:00:00

Adapting Our Exercise Talk: Key Tips on Counseling...

Diabetes Discourse ·

2023/03/02

Host: John Buse, MD, PhD Guest: Abbie E. Smith-Ryan, PhD, CSCS*D, FNSCA There are immeasurable benefits to exercise, but the hard part for patients may be getting started. How can we help our patients make exercise a part of their lives? Dr. John Buse speaks with Dr. Abbie Smith-Ryan, a Professor of Exercise Physiology at the University of North Carolina – Chapel Hill, about the key benefits of exercise and how to encourage them for various patient populations.

en

00:00:00

Insights from Obesity Canada: A Deep Dive into...

Diabetes Discourse ·

2023/01/26

Host: John Buse, MD, PhD Guest: Sue Pedersen, MD, FRCPC New guidelines published by Obesity Canada take a deep dive into pharmacotherapy and feature the latest recommendations on comorbidities and decision tools. To better understand the impact of these guidelines, Dr. John Buse speaks with one of the guidelines authors, Dr. Sue Pedersen, a specialist in endocrinology and metabolism.

en

00:00:00

Key Therapeutic Insights on Semaglutide in Adolescent...

Diabetes Discourse ·

2023/01/23

Host: John Buse, MD, PhD Guest: Silva Arslanian, MD New research on once-daily semaglutide for adolescent patients with obesity may alter clinicians’ approach to care. What do we need to know? Dr. John Buse speaks with one of the study’s investigators, Dr. Silva Arslanian, from the University of Pittsburgh to dive into this clinical data and explore how these results may change the treatment landscape.

en

00:00:00

Explore Impacts Of Glucose-Lowering Medications in...

Diabetes Discourse ·

2022/12/20

Host: John Buse, MD, PhD Guest: Jennifer B. Green, MD What does the latest research on glycemia reduction show us about the impact of glucose-lowering medication in combination with metformin on microvascular and cardiovascular outcomes in patients with type 2 diabetes? Dr. John Buse speaks with one of the study’s investigators, Dr. Jennifer Green, a Professor of Medicine at Duke University, about this emerging data.

en

00:00:00

Key Insights from GRADE: Exploring Data on Glycemia...

Diabetes Discourse ·

2022/12/12

Host: John Buse, MD, PhD Guest: Deborah Wexler, MD The GRADE study demonstrated the efficacy of different treatment options for patients with type 2 diabetes. To learn more about these treatment options, Dr. John Buse joins one of the study’s investigators, Dr. Deborah Wexler from Harvard Medical School and the Massachusetts General Hospital Diabetes Center, to dive into this study.

en

00:00:00

Breaking Down the Bionic Pancreas: A Device for...

Diabetes Discourse ·

2022/11/07

Host: John Buse, MD, PhD Guest: Steven Russell, MD, PhD Research continues to emerge on the bionic pancreas and its capabilities, and a recent study shows how it can count carbohydrates and lower A1c for patients with type 1 diabetes. To find out how it does, Dr. John Buse is joined by Dr. Steven Russell, an Associate Professor of Medicine at Harvard Medical School at the Massachusetts General Hospital.

en

00:00:00

An Assessment of Automated Insulin Delivery Systems...

Diabetes Discourse ·

2022/11/04

Host: John Buse, MD, PhD Guest: Martin de Bock, PhD FRACP Recent research has explored the efficacy of open source automated insulin delivery devices for patient with type 1 diabetes. What did these results tell us? Dr. John Buse speaks with Dr. Martin de Bock, a pediatric endocrinologist at the University of Otago in Christchurch, New Zealand, to dive deeper into this research.

en

00:00:00

A Look at Comprehensive Telehealth for PPDM

Diabetes Discourse ·

2022/10/28

Host: John Buse, MD, PhD Guest: Matthew Crowley, MD Can telehealth change the way we manage persistently controlled type 2 diabetes (PPDM)? Dr. John Buse speaks with Dr. Matt Crowley, an Associate Professor of Medicine in the Department of Medicine in the Division of Endocrinology, Metabolism and Nutrition at Duke University, to explore some of the research on different methods of telehealth.

en

00:00:00

SNAP, Food Insecurity, & Healthcare Spending: What Do...

Diabetes Discourse ·

2022/10/28

Host: John Buse, MD, PhD Guest: Seth Berkowitz, MD, MPH Food assistance programs like the Supplemental Nutrition Assistance Program (SNAP) can help relieve food insecurity. But can they also lower healthcare spending? To answer this question, Dr. John Buse sits down with Dr. Seth Berkowitz from the Division of General Medicine and Clinical Epidemiology at the University of North Carolina School of Medicine.

en

00:00:00

Getting to Know GRADE: A Comparative Study of T2D...

Diabetes Discourse ·

2022/10/25

Host: John Buse, MD, PhD Guest: Ashok Balasubramanyam, MD Researchers from the GRADE study zeroed in on islet autoimmunity in beta cell dysfunction for patients with type 2 diabetes. What did various treatment options show us? Dr. John Buse speaks with Dr. Ashok Balasubramanyam, a Professor in the Department of Endocrinology, Diabetes and Metabolism at Baylor College of Medicine.

en

00:00:00

Exploring Precision Medicine in the Treatment of...

Diabetes Discourse ·

2022/10/24

Host: John Buse, MD, PhD Guest: Jose C. Florez, MD, PhD Precision medicine may be the future of diabetes treatment. But what’s needed to implement this approach into practice? Here to explore this concept with Dr. John Buse is Dr. Jose Florez, Chief of the Endocrine Division and Diabetes Unit at the Massachusetts General Hospital.

en

00:00:00

Can Generic Drugs Be Repurposed for COVID-19 Treatment?

Diabetes Discourse ·

2022/10/24

Host: John Buse, MD, PhD Guest: Carolyn Bramante Emerging research has shed light on the possibility of generic drugs being repurposed for the treatment of COVID-19. Dr. John Buse discusses metformin, ivermectin, and fluvoxamine with Dr. Carolyn Bramante, an Assistant Professor in the Division of Geriatrics, Palliative and Primary Care at the University of Minnesota Medical School.

en

00:00:00

A Fight Against Obesity: Evaluating Clinical Data...

Diabetes Discourse ·

2022/08/17

Host: John Buse, MD, PhD Guest: Ania Jastreboff, MD, PhD In the ongoing battle against obesity, what does the SURMOUNT-1 study tell us about the role of tirzepatide? Dr. Ania Jastreboff, who is an Associate Professor of Medicine and the co-director of Weight Management and Obesity Prevention Program at Yale School of Medicine, chats with Dr. John Buse and this study’s findings.

en

00:00:00

Heart Failure Consensus Report: A Review of ADA...

Diabetes Discourse ·

2022/08/16

Host: John Buse, MD, PhD Guest: Rodica Pop-Busui, MD, PhD The American Diabetes Association (ADA) published a new consensus report with the American College of Cardiology on heart failure in patients with diabetes. What does this report recommend—and how will these recommendations impact clinical practice? Dr. John Buse speaks with Dr. Rodica Pop-Busui from the University of Michigan about these updated heart failure recommendations.

en

00:00:00

Exploring AACE Updates on the Management of NAFLD & NASH

Diabetes Discourse ·

2022/08/11

Host: John Buse, MD, PhD Guest: Kenneth Cusi, MD, FACP, FACE The American Association of Clinical Endocrinology (AACE) released new recommendations for the diagnosis and management of NAFLD and NASH. To learn more about these updates, Dr. John Buse speaks with Dr. Kenneth Cusi, who is the Chief of the Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine at the University of Florida.

en

00:00:00

The IRIS Trial: Reviewing Results & Taking a Look at...

Diabetes Discourse ·

2022/08/11

Host: John Buse, MD, PhD Guest: David Spence, MD Pioglitazone was studied in the Insulin Resistance Intervention after Stroke trial, or IRIS for short. What do we need to know about it? Joining Dr. John Buse to share background and clinical data of the impacts observed is Dr. David Spence, a Professor Emeritus of Neurology and Clinical Pharmacology at Western University and the Director of the Stroke Prevention and Atherosclerosis Research Center in London, Ontario.

en

00:00:00

Investigating Interventions: The Role of Lifestyle...

Diabetes Discourse ·

2022/05/20

Host: John Buse, MD, PhD Guest: Samuel Dagogo-Jack, MD, DSc Intensive lifestyle interventions have shown to, if not prevent, significantly delay the onset of diabetes. But what do we need to know about these interventions? Joining Dr. John Buse to share clinical data and unravel the impacts of interventions in prediabetic patients is Dr. Samuel Dagogo-Jack from the University of Tennessee Health Sciences Center.

en

00:00:00

Exploring A New Anti-Obesity Treatment

Diabetes Discourse ·

2022/05/12

Host: John Buse, MD, PhD Guest: Domenica M. Rubino, MD The obesity epidemic affects millions of patients around the world, but a new treatment option may be a game-changer for the treatment landscape. Lead author of the STEP 8 clinical trial, Dr. Domenica Rubino, joins Dr. John Buse to share the insights from this drug trial and how these key clinical findings may impact the obesity treatment landscape.

en

00:00:00

Exploring the Deintensification of...

Diabetes Discourse ·

2022/04/21

Host: John Buse, MD, PhD Guest: Anastasia-Stefania Alexopoulos, MBBS, MHS Dr. John Buse joins Dr. Anastasia-Stefania Alexopoulos, an endocrinologist, researcher, and Assistant Professor of Medicine in the Department of Medicine at Duke University School of Medicine to share her research on the deintensification of hypoglycemia-inducing medications in diabetic adults.

en

00:00:00

Investigating the T1D Increase: A Look at Rising...

Diabetes Discourse ·

2022/04/11

Host: Carol Wysham Guest: Jane J. Kim, M.D. Since 2020, pediatricians have seen a rapid rise in new-onset type 1 diabetes in children. Is this due to the COVID-19 pandemic or an indirect consequence of it? To answer this question, Dr. Jane Kim, a pediatric endocrinologist at Rady Children's Hospital in San Diego, shares what kind of correlation she's seeing.

en

203 results

Similar Podcasts

النشرة العلمية

مونت كارلو الدولية / MCD

Ciência

RFI Português

天方烨谈

基因频道

Quilo de Ciencia - Cienciaes.com

Jorge Laborda

The Field Guides

The Field Guides